VBIV Stock Price, VBI Vaccines Inc Quote, Chart

Market Summary

USD0.59-0.02

Market Closed

-3.28%

VBIV Stock Price

View Fullscreen

VBIV RSI Chart

VBIV Valuation

Market Cap

15.1M

Price/Earnings (Trailing)

-0.16

Price/Sales (Trailing)

1.74

EV/EBITDA

-0.18

Price/Free Cashflow

-0.24

VBIV Price/Sales (Trailing)

VBIV Profitability

Operating Margin

-5.60%

EBT Margin

-1069.29%

Return on Equity

-1.2K%

Return on Assets

-106.77%

Free Cashflow Yield

-409.78%

VBIV Fundamentals

VBIV Revenue

Revenue (TTM)

8.7M

Rev. Growth (Yr)

191.13%

Rev. Growth (Qtr)

-87.12%

VBIV Earnings

Earnings (TTM)

-92.8M

Earnings Growth (Yr)

99.94%

Earnings Growth (Qtr)

99.94%

Breaking Down VBIV Revenue

Last 7 days

-1.6%

Last 30 days

5.2%

How does VBIV drawdown profile look like?

VBIV Financial Health

Current Ratio

0.48

VBIV Investor Care

Shares Dilution (1Y)

177.85%

Diluted EPS (TTM)

-7.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.4M	1.8M	8.1M	8.7M
2022	456.0K	660.0K	870.0K	1.1M
2021	947.0K	905.0K	714.0K	631.0K
2020	2.3M	1.8M	1.5M	1.1M
2019	3.5M	3.9M	4.3M	2.2M
2018	916.0K	806.0K	872.0K	3.4M
2017	627.0K	889.0K	801.0K	865.0K
2016	853.3K	751.5K	649.8K	548.0K
2015	0	0	0	955.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Which funds bought or sold VBIV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	-	1.00	-%
Apr 23, 2024	WETZEL INVESTMENT ADVISORS, INC.	added	200	889	1,889	-%
Apr 12, 2024	AdvisorNet Financial, Inc	unchanged	-	-	5.00	-%
Apr 11, 2024	CITY HOLDING CO	unchanged	-	-	19.00	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	reduced	-6.68	-147	681	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	-32.00	245	-%
Mar 11, 2024	VANGUARD GROUP INC	added	185	65,371	108,356	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	new	-	35,678	35,678	-%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	unchanged	-	-110,508	814,999	0.02%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	42,564	42,564	-%

Are Funds Buying or Selling VBIV?

Are funds buying VBIV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VBIV

No. of Funds

Unveiling VBI Vaccines Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 17, 2024	perceptive advisors llc	4.4%	1,261,710	SC 13D/A
Nov 20, 2023	perceptive advisors llc	5.8%	1,381,355	SC 13D/A
Jul 25, 2023	arch venture fund vi lp	-	0	SC 13D/A
Feb 11, 2021	state street corp	9.21%	22,293,634	SC 13G
Feb 02, 2021	blackrock inc.	5.4%	13,175,944	SC 13G
Jun 09, 2020	blackrock inc.	4.8%	11,147,480	SC 13G/A
Apr 28, 2020	perceptive advisors llc	25.3%	57,111,289	SC 13D/A
Feb 14, 2020	biotechnology value fund l p	-	0	SC 13G/A
Feb 07, 2020	blackrock inc.	5.8%	10,337,329	SC 13G
Oct 10, 2019	arch venture fund vi lp	7.3%	13,026,057	SC 13D/A

Recent SEC filings of VBI Vaccines Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	SC 13D/A	13D - Major Acquisition
Apr 16, 2024	8-K	Current Report
Apr 16, 2024	10-K	Annual Report
Apr 11, 2024	8-K	Current Report
Apr 11, 2024	424B5	Prospectus Filed
Apr 03, 2024	8-K	Current Report
Apr 02, 2024	8-K	Current Report
Mar 28, 2024	NT 10-K	NT 10-K
Feb 14, 2024	8-K	Current Report
Feb 06, 2024	8-K	Current Report

Peers (Alternatives to VBI Vaccines Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-12.04%	-45.12%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-13.93%	67.39%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.40%	-0.33%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-6.74%	-16.88%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

VBI Vaccines Inc News

Latest updates

VBI Vaccines Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-87.1%	853,000	6,624,000	720,000	485,000	293,000	317,000	346,000	126,000	81,000	107,000	142,000	301,000	164,000	298,000	184,000	415,000	574,000	647,000	640,000	360,000	2,684,000
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	2,420,500	2,111,000	2,060,000	2,577,000	2,489,500	1,977,000	2,354,000	1,179,000	1,228,000
Operating Expenses	-14.8%	14,215,500	16,693,000	37,692,000	19,994,000	21,732,000	21,875,000	23,249,000	16,046,000	20,952,000	15,131,000	16,583,000	15,998,000	14,374,500	12,151,000	8,326,000	9,828,000	10,742,000	16,790,000	12,909,000	14,179,000	21,192,500
S&GA Expenses	-1.4%	8,906,000	9,036,000	10,917,000	13,284,000	15,886,000	14,220,000	15,084,000	10,930,000	12,528,000	9,693,000	9,367,000	6,747,000	7,130,500	5,562,000	3,901,000	4,058,000	-2,476,000	9,412,000	3,194,000	3,960,000	9,604,500
R&D Expenses	-10.7%	1,368,000	1,532,000	3,292,000	3,151,000	2,518,000	4,983,000	5,643,000	2,362,000	5,165,500	2,972,000	4,582,000	6,839,000	4,823,500	4,478,000	2,365,000	3,193,000	4,436,500	5,401,000	7,361,000	9,040,000	10,082,000
EBITDA Margin	25.3%	-9.76	-13.06	-61.36	-78.56	-99.11	-120	-145	-148	-100	-85.13	-64.36	-53.35	-40.16	-	-	-	-	-	-	-	-
Interest Expenses	-6.0%	1,450,000	1,543,000	1,708,000	1,429,000	1,208,000	958,000	901,000	940,000	1,049,000	1,026,000	845,000	1,812,000	65,000	742,000	682,000	475,000	524,000	626,000	566,000	480,000	701,000
Earnings Before Taxes	99.9%	-13,000	-20,444,000	-44,628,000	-27,751,000	-21,141,000	-25,209,000	-45,699,000	-21,254,000	-18,783,000	-15,847,000	-17,476,000	-17,647,000	-15,362,000	-12,997,000	-9,513,000	-8,358,000	-10,875,000	-16,162,000	-13,170,000	-14,606,000	-19,249,000
EBT Margin	23.8%	-10.69	-14.03	-65.42	-83.14	-104	-127	-153	-160	-110	-92.90	-70.15	-58.63	-43.57	-	-	-	-	-	-	-	-
Net Income	99.9%	-13,000	-20,444,000	-44,628,000	-27,751,000	-21,141,000	-25,209,000	-45,699,000	-21,254,000	-18,783,000	-15,847,000	-17,476,000	-17,647,000	-15,362,000	-12,997,000	-9,513,000	-8,358,000	-10,875,000	-16,162,000	-13,170,000	-14,606,000	-19,249,000
Net Income Margin	23.8%	-10.69	-14.03	-65.42	-83.14	-104	-127	-153	-160	-110	-92.90	-70.15	-58.63	-43.57	-	-	-	-	-	-	-	-
Free Cashflow	-51.5%	-12,227,000	-8,073,000	-19,260,000	-22,190,000	-20,498,000	-18,574,000	-18,527,000	-20,440,000	-19,126,000	-4,455,000	-11,122,000	-7,200,000	-17,027,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-13.7%	87.00	101	88.00	128	155	172	172	194	210	224	225	223	209	200	161	107	122	132	115	126	138
Current Assets	-27.8%	36.00	50.00	32.00	52.00	78.00	96.00	93.00	112	130	148	146	146	132	126	89.00	38.00	47.00	57.00	33.00	46.00	62.00
Cash Equivalents	-100.0%	-	35.00	21.00	40.00	63.00	84.00	82.00	101	122	137	135	108	94.00	95.00	61.00	36.00	44.00	53.00	30.00	43.00	59.00
Inventory	12.7%	8.00	8.00	7.00	7.00	7.00	6.00	4.00	4.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Net PPE	2.6%	10.00	9.00	10.00	12.00	12.00	11.00	11.00	11.00	11.00	10.00	10.00	10.00	11.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	9.00
Goodwill	-46.7%	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	9.00	8.00	8.00
Current Liabilities	-1.9%	76.00	77.00	28.00	30.00	37.00	35.00	41.00	34.00	33.00	33.00	26.00	24.00	17.00	14.00	15.00	29.00	30.00	30.00	35.00	23.00	23.00
Long Term Debt	-	-	-	48.00	49.00	49.00	48.00	21.00	25.00	28.00	28.00	27.00	16.00	16.00	16.00	15.00	-	-	-	-	-	-
LT Debt, Current	0.9%	51.00	50.00	2.00	-	-	-	9.00	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	48.00	49.00	49.00	48.00	21.00	25.00	28.00	28.00	27.00	16.00	16.00	16.00	15.00	-	-	-	-	-	-
Shareholder's Equity	-62.1%	8.00	20.00	9.00	45.00	64.00	84.00	106	130	144	160	168	180	172	166	127	74.00	88.00	97.00	76.00	87.00	98.00
Retained Earnings	0.0%	-582	-582	-561	-517	-489	-468	-443	-397	-378	-359	-343	-326	-308	-293	-280	-270	-262	-251	-235	-222	-207
Additional Paid-In Capital	1.4%	107	106	94.00	92.00	90.00	88.00	84.00	81.00	82.00	79.00	77.00	78.00	76.00	74.00	73.00	67.00	66.00	66.00	65.00	64.00	63.00
Shares Outstanding	2.5%	24.00	23.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	8.00	8.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	22.00	-	-	-	155	-	-	-	621	-	-	-	499	-	-	-	79.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-51.5%	-12,057	-7,960	-19,210	-21,656	-19,046	-17,274	-17,450	-19,925	-18,516	-4,030	-10,718	-6,644	-16,495	-15,100	-7,807	-7,648	-8,530	-13,878	-12,284	-14,020	-7,550
Share Based Compensation	-1.6%	1,476	1,500	1,674	2,011	2,327	2,412	2,457	2,502	2,537	2,529	2,423	2,139	1,533	1,493	1,074	1,187	815	876	982	1,262	624
Cashflow From Investing	-50.4%	-170	-113	-50.00	-534	-1,452	-1,300	-1,077	-515	-610	-425	24,747	-556	-532	-200	-25,135	-133	-186	-586	-1,005	-1,896	-2,374
Cashflow From Financing	-	272	-	-	-	-	19,437	-	12.00	2,892	7,055	12,722	21,624	15,525	49,294	58,173	-600	-79.00	-	-	-	43,552

VBIV Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues, net	$ 8,682	$ 1,082
Operating expenses:
Cost of revenues	12,507	11,276
Research and development	9,343	15,506
Sales, general and administrative	42,143	56,120
Impairment charges	24,600
Total operating expenses	88,593	82,902
Loss from operations	(79,911)	(81,820)
Interest expense, net of interest income	(6,401)	(4,007)
Foreign exchange loss	(6,524)	(27,476)
Loss before income taxes	(92,836)	(113,303)
Income tax expense
NET LOSS	(92,836)	(113,303)
Deemed dividend on certain warrants	(1,005)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	(93,841)	(113,303)
Other comprehensive income	6,887	23,005
COMPREHENSIVE LOSS	$ (85,949)	$ (90,298)
Net loss per share of common shares, basic	$ (6.03)
Net loss per share of common shares, diluted	$ (6.03)	$ (13.16)
Weighted-average number of common shares outstanding, basic	15,572,494
Weighted-average number of common shares outstanding, diluted	15,572,494	8,608,530

VBIV Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash	$ 23,685	$ 62,629
Accounts receivable, net		94
Inventory, net	8,499	6,599
Prepaid expenses	2,284	2,309
Other current assets	1,763	6,059
Total current assets	36,231	77,690
NON-CURRENT ASSETS
Other long-term assets	1,178	1,355
Property and equipment, net	9,665	12,253
Right of use assets	2,248	3,316
Intangible assets, net	36,499	58,345
Goodwill	1,130	2,127
Total non-current assets	50,720	77,396
TOTAL ASSETS	86,951	155,086
CURRENT LIABILITIES
Accounts payable	6,431	12,973
Other current liabilities	10,284	22,588
Current portion of deferred revenues	7,276	409
Current portion of lease liability	976	972
Current portion of long-term debt, net of debt discount	50,769
Total current liabilities	75,736	36,942
NON-CURRENT LIABILITIES
Deferred revenues, net of current portion	1,832	2,204
Lease liability, net of current portion	1,295	2,365
Long-term debt, net of debt discount		48,888
Liabilities for severance pay	561	524
Total non-current liabilities	3,688	53,981
COMMITMENTS AND CONTINGENCIES (NOTE 17)
STOCKHOLDERS’ EQUITY
Common shares (unlimited authorized; no par value) (2023 issued and outstanding – 23,918,983; 2022 issued and outstanding – 8,608,539)	454,214	442,312
Additional paid-in capital	107,431	90,020
Accumulated other comprehensive income	28,327	21,440
Accumulated deficit	(582,445)	(489,609)
Total stockholders’ equity	7,527	64,163
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 86,951	$ 155,086

About VBI Vaccines Inc

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

CEO	Mr. Jeffery R. Baxter FCMA
WEBSITE	vbivaccines.com
INDUSTRY	Biotechnology
EMPLOYEES	190

VBI Vaccines Inc Frequently Asked Questions

What is the ticker symbol for VBI Vaccines Inc? What does VBIV stand for in stocks?

VBIV is the stock ticker symbol of VBI Vaccines Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of VBI Vaccines Inc (VBIV)?

As of Tue Apr 23 2024, market cap of VBI Vaccines Inc is 15.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VBIV stock?

You can check VBIV's fair value in chart for subscribers.

What is the fair value of VBIV stock?

You can check VBIV's fair value in chart for subscribers. The fair value of VBI Vaccines Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of VBI Vaccines Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VBIV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is VBI Vaccines Inc a good stock to buy?

The fair value guage provides a quick view whether VBIV is over valued or under valued. Whether VBI Vaccines Inc is cheap or expensive depends on the assumptions which impact VBI Vaccines Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VBIV.

What is VBI Vaccines Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, VBIV's PE ratio (Price to Earnings) is -0.16 and Price to Sales (PS) ratio is 1.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VBIV PE ratio will change depending on the future growth rate expectations of investors.